SEC CIK 1055951

ORBIMED ADVISORS LLC

Reported ownership across 7 companies, sourced from SEC Form 4 filings and updated daily.

Current Positions

CompanyShares OwnedAs Of
SYBXview stock →3,696,6622021-04-20
KALAview stock →3,447,8402018-02-08
RYTMview stock →2,751,6792018-05-22
NTLAview stock →2,603,6462016-05-11
PCRXview stock →2,446,0002012-03-12
SUPNview stock →817,0002013-02-13
AMRNview stock →594,3002012-09-04

Position History — PCRX

Reported shares owned immediately after each Form 4 transaction, over time.

0942,9801,885,9612,828,9412011-022011-022011-022012-022012-022012-022012-032012-03

Recent Filings — PCRX

DateActivitySharesPriceOwned After
2012-03-12Open-market sale700$11.032,446,000
2012-03-12Open-market sale62,400$11.032,446,700
2012-03-09Open-market sale300$11.252,509,100
2012-03-09Open-market sale36,700$11.252,509,400
2012-02-29Open-market sale3,000$10.862,546,100
2012-02-28Open-market sale10,000$11.122,549,200
2012-02-28Open-market sale100$11.122,549,100
2012-02-27Open-market sale28,700$11.052,559,500
2012-02-27Open-market sale300$11.052,559,200
2012-02-03Open-market sale500$10.792,588,200
2012-02-03Open-market sale49,500$10.792,588,700
2012-02-02Open-market sale23,100$10.852,638,400
2012-02-02Open-market sale200$10.852,638,200
2012-02-01Open-market sale700$11.012,661,500
2012-02-01Open-market sale69,300$11.012,662,200
2011-10-31Open-market sale887$10.532,731,500
2011-10-31Open-market sale96,554$10.532,732,387
2011-02-08Conversion (derivative)1,473,645$0.000
2011-02-08Conversion (derivative)705,845$0.000
2011-02-08Conversion (derivative)14,035$0.000
2011-02-08Open-market buy2,526$7.002,561,084
2011-02-08Open-market buy2,527$7.002,828,941
2011-02-08Open-market buy265,330$7.002,826,414
2011-02-08Conversion1,473,645—1,566,625
2011-02-08Open-market buy265,331$7.002,558,558
2011-02-08Conversion6,722$13.442,293,227
2011-02-08Conversion705,845$13.442,286,505
2011-02-08Conversion14,035—1,580,660
2011-02-02———877
2011-02-02———92,103

Source: SEC EDGAR Form 4 filings. For informational purposes only — not investment advice.